[1]
|
Glubb, D.M., Thompson, D.J., Aben, K.K.H., et al. (2020) Cross-Cancer Genome-Wide Association Study of Endome-trial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Can-cer Epidemiology, Biomarkers & Prevention, 30, 217-228. https://doi.org/10.1158/1055-9965.EPI-20-0739
|
[2]
|
Colombo, N., Creutzberg, C., Amant, F., et al. (2016) ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Interna-tional Journal of Gynecological Cancer, 26, 2-30.
https://doi.org/10.1097/IGC.0000000000000609
|
[3]
|
Njoku, K., Abiola, J., Russell, J. and Crosbie, E.J. (2020) Endometrial Cancer Prevention in High-Risk Women. Best Practice & Research Clinical Obstetrics & Gynaecology, 65, 66-78. https://doi.org/10.1016/j.bpobgyn.2019.12.005
|
[4]
|
邹纯静, 罗庆, 吴谋喜, 等. 血清HE4和CA125预测子宫内膜癌患者不良预后的价值[J]. 中国妇幼保健, 2018, 33(8): 1707-1710.
|
[5]
|
Paunovic, V., Protrka, Z., Ardalic, D. and Paunovic, T. (2017) Usefulness of Human Epididymis Protein 4 in Predicting Optimal Cytoreductive Therapy in Patients with Advanced Ovarian Cancer. Journal of the Balkan Union of Oncology, 22, 29-33.
|
[6]
|
Alkushi, A., Irving, J., Hsu, F., et al. (2003) Immunoprofile of Cervical and Endometrial Adenocarcinomas Using a Tissue Mi-croarray. Virchows Archiv, 442, 271-277. https://doi.org/10.1007/s00428-002-0752-4
|
[7]
|
Kirchhoff, C., Habben, I., Ivell, R. and Krull, N. (1991) A Major Human Epididymis-Specific cDNA Encodes a Protein with Sequence Homol-ogy to Extracellular Proteinase Inhibitors. Biology of Reproduction, 45, 350-357.
https://doi.org/10.1095/biolreprod45.2.350
|
[8]
|
Galgano, M.T., Hampton, G.M. and Frierson, H.F. (2006) Com-prehensive Analysis of HE4 Expression in Normal and Malignant Human Tissues. Modern Pathology, 19, 847-853. https://doi.org/10.1038/modpathol.3800612
|
[9]
|
Iwahori, K., Suzuki, H., Kishi, Y., et al. (2012) Serum HE4 as a Diagnostic and Prognostic Marker for Lung Cancer. Tumour Biology, 33, 1141-1149. https://doi.org/10.1007/s13277-012-0356-9
|
[10]
|
Wang, X., Fan, Y., Wang, J., Wang, H. and Liu, W. (2014) Eval-uating the Expression and Diagnostic Value of Human Epididymis Protein 4 (HE4) in Small Cell Lung Cancer. Tumour Biology, 35, 6847-6853.
https://doi.org/10.1007/s13277-014-1943-8
|
[11]
|
Wojcik, E., Tarapacz, J., Rychlik, U., et al. (2016) Human Epidi-dymis Protein 4 (HE4) in Patients with Small-Cell Lung Cancer. Clinical Laboratory, 62, 1625-1632. https://doi.org/10.7754/Clin.Lab.2016.151212
|
[12]
|
Lu, M., Ju, S., Shen, X., et al. (2017) Combined Detection of Plasma miR-127-3p and HE4 Improves the Diagnostic Efficacy of Breast Cancer. Cancer Biomarkers, 18, 143-148. https://doi.org/10.3233/CBM-160024
|
[13]
|
Dai, H.-Y., Hu, F. and Ding, Y. (2021) Diagnostic Value of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in the Patients with Ovarian Carcinoma: A Protocol for Systematic Review and Meta-Analysis. Medicine, 100, e25981. https://doi.org/10.1097/MD.0000000000025981
|
[14]
|
Liu, J., Han, L. and Jiao, Z. (2021) The Diagnostic Value of Human Epididymis Protein 4 for Endometrial Cancer Is Moderate. Scientific Reports, 11, Article No. 575. https://doi.org/10.1038/s41598-020-79960-1
|
[15]
|
Moore, R.G., Mcmeekin, D.S., Brown, A.K., et al. (2009) A Novel Multiple Marker Bioassay Utilizing HE4 and CA125 for the Pre-diction of Ovarian Cancer in Patients with a Pelvic Mass. Gynecologic Oncology, 112, 40-46.
https://doi.org/10.1016/j.ygyno.2008.08.031
|
[16]
|
Degez, M., Caillon, H., Chauviré-Drouard, A., et al. (2021) En-dometrial Cancer: A Systematic Review of HE4, REM and REM-B. Clinica Chimica Acta, 515, 27-36. https://doi.org/10.1016/j.cca.2020.12.029
|
[17]
|
Yilmaz, S.A., Altınkaya, S.Ö., Kerimoglu, Ö.S., et al. (2017) The Role of Human Epididymis Secretory Protein E4 in Patients with Endometrial Cancer and Premalignant Endometrial Le-sions. Journal of Obstetrics and Gynaecology, 37, 58-63. https://doi.org/10.3109/01443615.2016.1174199
|
[18]
|
闫跃. 外周血NLR、PLR及血清CA125、HE4与子宫内膜癌转移及分期关系的研究[D]: [硕士学位论文]. 沈阳: 中国医科大学, 2021.
|
[19]
|
Kalogera, E., Scholler, N., Powless, C., et al. (2012) Correlation of Serum HE4 with Tumor Size and Myometrial Invasion in Endometrial Cancer. Gynecologic Oncology, 124, 270-275. https://doi.org/10.1016/j.ygyno.2011.10.025
|
[20]
|
Brennan, D.J., Hackethal, A., Metcalf, A.M., et al. (2014) Serum HE4 as A Prognostic Marker in Endometrial Cancer—A Population Based Study. Gynecologic Oncology, 132, 159-165. https://doi.org/10.1016/j.ygyno.2013.10.036
|
[21]
|
Rajadevan, N., McNally, O., Neesham, D., Richards, A. and Naaman, Y. (2021) Prognostic Value of Serum HE4 Level in the Management of Endometrial Cancer: A Pilot Study. Australian and New Zealand Journal of Obstetrics and Gynaecology, 61, 284-289. https://doi.org/10.1111/ajo.13302
|
[22]
|
Abbink, K., Zusterzeel, P., Geurts-Moespot, A., et al. (2019) HE4 Is Supe-rior to CA125 in the Detection of Recurrent Disease in the Follow-up of High Risk Endometrial Cancer Patients. Euro-pean Journal of Obstetrics & Gynecology and Reproductive Biology, 234, e117. https://doi.org/10.1016/j.ejogrb.2018.08.415
|
[23]
|
Wang, Y., Han, C., Teng, F., Bai, Z., Tian, W. and Xue, F. (2017) Predictive Value of Serum HE4 and CA125 Concentrations for Lymphatic Metastasis of Endometrial Cancer. Interna-tional Journal of Gynecology & Obstetrics, 136, 58-63. https://doi.org/10.1002/ijgo.12010
|
[24]
|
Gąsiorowska, E., Magnowska, M., Iżycka, N., Warchoł, W. and Nowak-Markwitz, E. (2016) The Role of HE4 in Differentiating Benign and Malignant Endometrial Pathology. Ginekologia Polska, 87, 260-264.
https://doi.org/10.17772/gp/62356
|
[25]
|
O’Toole, S.A., Huang, Y., Norris, L., et al. (2021) HE4 and CA125 as Preoperative Risk Stratifiers for Lymph Node Metastasis in Endometrioid Carcinoma of the Endometrium: A Retrospec-tive Study in a Cohort with Histological Proof of Lymph Node Status. Gynecologic Oncology, 160, 514-519. https://doi.org/10.1016/j.ygyno.2020.11.004
|
[26]
|
王锦, 俞虹, 何建新, 等. 血清和子宫内膜组织CA125和HE4在子宫内膜癌术前评估及不同病理特征中的变化意义[J]. 中国妇幼保健, 2021, 36(11): 2506-2508.
|
[27]
|
Li, J., Chen, H., Mariani, A., et al. (2013) HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. In-ternational Journal of Molecular Sciences, 14, 6026-6043. https://doi.org/10.3390/ijms14036026
|
[28]
|
Cymbaluk-Płoska, A., Gargulińska, P., Bulsa, M., et al. (2021) Can the Determination of HE4 and CA125 Markers Affect the Treatment of Patients with Endometrial Cancer? Diagnostics, 11, Article No. 626.
https://doi.org/10.3390/diagnostics11040626
|
[29]
|
Renner, A.B., Dietrich-Ntoukas, T. and Jägle, H. (2015) Recur-rent Episodes of Night Blindness in a Patient with Short Bowel Syndrome. Documenta Ophthalmologica, 131, 221-230. https://doi.org/10.1007/s10633-015-9516-8
|
[30]
|
龚惠, 金玉华, 何萍, 等. 波形蛋白的表达与子宫内膜癌患者术后预后的关系[J]. 现代生物医学进展, 2017, 17(33): 6460-6464, 6490.
|
[31]
|
吕嘉, 宋力雯, 丘瑾, 等. 雌激素受体孕激素受体和波形蛋白在子宫内膜癌的表达及临床意义[J]. 山西医药杂志, 2015, 44(24): 2843-2846.
|
[32]
|
Liu, C.H., Jiang, Q.P., Lin, D., Chen, W., Xiao, Y.Y., Lin, L., Deng, Y.R., Jiang, H.P. and Guo, S.Q. (2016) Coexpression of MAP2K4 and Vimentin Proteins in Human Endometrial Carcinoma and Its Clinicopatho-logical Significance. Journal of Southern Medical University, 37, 157-164. (In Chinese)
|
[33]
|
Kidd, M.E., Shumaker, D.K. and Ridge, K.M. (2014) The Role of Vimentin Intermediate Filaments in the Progression of Lung Cancer. American Journal of Respiratory Cell and Molecular Biology, 50, 1-6.
https://doi.org/10.1165/rcmb.2013-0314TR
|
[34]
|
Domagala, W., Striker, G., Szadowska, A., et al. (1994) P53 Pro-tein and Vimentin M Invasive Ductal Nos Breast Carcinoma—Relationship with Survival and Sites of Metastases. Euro-pean Journal of Cancer, 30, 1527-1534.
https://doi.org/10.1016/0959-8049(94)00288-G
|
[35]
|
Danielsson, F., Peterson, M.K., Araújo, H.C., Lautenschläger, F. and Gad, A.K.B. (2018) Vimentin Diversity in Health and Disease. Cells, 7, Article No. 147. https://doi.org/10.3390/cells7100147
|
[36]
|
Mendez, M.G., Kojima, S.-I. and Goldman, R.D. (2010) Vimentin In-duces Changes in Cell Shape, Motility, and Adhesion During the Epithelial to Mesenchymal Transition. The FASEB Journal, 24, 1838-1851.
https://doi.org/10.1096/fj.09-151639
|
[37]
|
Ivaska, J. (2011) Vimentin: Central Hub in EMT Induction? Small GTPases, 2, 51-53.
https://doi.org/10.4161/sgtp.2.1.15114
|
[38]
|
Hoffmann, A., Ciani, E., Boeckardt, J., et al. (2003) Transcriptional Activities of the Zinc Finger Protein Zac Are Differentially Controlled by DNA Binding. Molecular and Cellular Biology, 23, 988-1003.
https://doi.org/10.1128/MCB.23.3.988-1003.2003
|
[39]
|
赵静, 刘国雄, 刘宝全. 波形蛋白和Ki-67在宫颈鳞状细胞癌中的表达及其相关性[J]. 山西医药杂志, 2016, 45(1): 17-19.
|
[40]
|
Zhou, W., Wang, K., Wang, J., et al. (2019) SOX17 Inhibits Tumor Metastasis Via Wnt Signaling in Endometrial Cancer. Oncotargets and Therapy, 12, 8275-8286. https://doi.org/10.2147/OTT.S220536
|
[41]
|
Yoriki, K., Mori, T., Kokabu, T., et al. (2019) Estrogen-Related Recep-tor Alpha Induces Epithelial-Mesenchymal Transition through Cancer-Stromal Interactions in Endometrial Cancer. Scien-tific Reports, 9, Article No. 6697.
https://doi.org/10.1038/s41598-019-43261-z
|
[42]
|
Wik, E., Ræder, M.B., Krakstad, C., et al. (2013) Lack of Estro-gen Receptor-α Is Associated with Epithelial-Mesenchymal Transition and PI3K Alterations in Endometrial Carcinoma. Clinical Cancer Research, 19, 1094-1105.
https://doi.org/10.1158/1078-0432.CCR-12-3039
|
[43]
|
Lachej, N., Jonušienė, V., Mažeikė, A., et al. (2019) Changes in the Expression of Notch and Wnt Signalling Molecules in Human Endometrial Cancer. Acta Medica Lituani-ca, 26, 181-190.
https://doi.org/10.6001/actamedica.v26i3.4148
|
[44]
|
Ye, L., Wang, X. and Li, B. (2021) Expression Profile of Epi-thelial-Mesenchymal Transition-Related Genes as a Prognostic Biomarker for Endometrial Cancer. Journal of Cancer, 12, 6484-6496. https://doi.org/10.7150/jca.62729
|
[45]
|
De Craene, B. and Berx, G. (2013) Regulatory Networks De-fining EMT during Cancer Initiation and Progression. Nature Reviews Cancer, 13, 97-110. https://doi.org/10.1038/nrc3447
|
[46]
|
Takai, M., Terai, Y., Kawaguchi, H., et al. (2014) The EMT (Epitheli-al-Mesenchymal-Transition)-Related Protein Expression Indicates the Metastatic Status and Prognosis in Patients with Ovarian Cancer. Journal of Ovarian Research, 7, Article No. 76. https://doi.org/10.1186/1757-2215-7-76
|
[47]
|
Zhang, X., Cao, G., Diao, X., et al. (2022) Vimentin Protein in Situ Expression Predicts Less Tumor Metastasis and Overall Better Survival of Endometrial Carcinoma. Disease Markers, 2022, Article ID: 5240046.
https://doi.org/10.1155/2022/5240046
|
[48]
|
Papadopoulos, N., Kotini, A., Cheva, A., et al. (2002) Immunohisto-chemical Expression of Vimentin and Secretory Component Antigens in Endometrial Hyperplasia and Neoplasia. Euro-pean Journal of Gynaecological Oncology, 23, 411-414.
|
[49]
|
Nesina, I.P., Iurchenko, N.P. and Buchynska, L.G. (2018) Markers of the Epithelial-Mesenchymal Transition in Cells of Endometrial Carcinoma. Experimental Oncology, 40, 218-222.
https://doi.org/10.31768/2312-8852.2018.40(3):218-222
|